Routine beta‐blocker therapy after acute coronary syndromes: The end of an era?
European Journal of Clinical Investigation · 2024
DOI: 10.1111/eci.14309 ↗At a glance
Übersichtsarbeit in European Journal of Clinical Investigation, 2024. Written by Nicolas Johner and 2 co-authors. Institution: Cardiology Division, Geneva University Hospitals, Geneva, Switzerland. Major MEDLINE topics: Acute Coronary Syndrome, Adrenergic beta-Antagonists. Cited 9 times so far (Crossref); 82 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Background
Beta‐blocker therapy, a treatment burdened by side effects including fatigue, erectile dysfunction and depression, was shown to reduce mortality and cardiovascular events after acute coronary syndromes (ACS) in the pre‐coronary reperfusion era. Potential mechanisms include protection from ventricular arrhythmias, increased ischaemia threshold and prevention of left ventricular (LV) adverse remodelling. With the advent of early mechanical reperfusion and contemporary pharmacologic secondary prevention, the benefit of beta‐blockers after ACS in the absence of LV dysfunction has been challenged.
Methods
The present narrative review discusses the contemporary evidence based on searching the PubMed database and references in identified articles.
Results
Recently, the REDUCE‐AMI trial—the first adequately powered randomized trial in the reperfusion era to test beta‐blocker therapy after myocardial infarction with preserved left ventricular ejection fraction (LVEF)—showed no benefit on the composite of all‐cause death or myocardial infarction over a median 3.5‐year follow‐up. While the benefit of beta‐blockers in patients with reduced LVEF remains undisputed, their value in post‐ACS patients with mildly reduced systolic function (LVEF 41%–49%) has not been studied in contemporary randomized trials; in this setting, observational studies have suggested a reduction in cardiovascular events with these agents. The adequate duration of beta‐blocker therapy remains unknown, but observational data suggests that any mortality benefit may be lost beyond 1–12 months after ACS in patients with LVEF >40%.
Conclusion
We believe that there is sufficient evidence to abandon routine beta‐blocker prescription in post‐ACS patients with preserved LV systolic function.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Cardiology Division, Geneva University Hospitals, Geneva, Switzerland.
- Institute of Primary Healthcare (BIHAM), University of Bern, Bern, Switzerland.
- Department of Cardiology, Lausanne University Hospital, Lausanne, Switzerland.
ORCID profiles: Nicolas Johner, Baris Gencer, Marco Roffi
Cite
APA
Johner, N., Gencer, B., & Roffi, M. (2024). Routine beta‐blocker therapy after acute coronary syndromes: The end of an era?. European Journal of Clinical Investigation. https://doi.org/10.1111/eci.14309
Vancouver
Johner N, Gencer B, Roffi M. Routine beta‐blocker therapy after acute coronary syndromes: The end of an era?. European Journal of Clinical Investigation. 2024. doi:10.1111/eci.14309
BibTeX
@article{Johner2024,
author = {Johner, Nicolas and Gencer, Baris and Roffi, Marco},
title = {Routine beta‐blocker therapy after acute coronary syndromes: The end of an era?},
journal = {European Journal of Clinical Investigation},
year = {2024},
doi = {10.1111/eci.14309}
}
EUVIMED